• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Moody’s upgrades Boston Scientific, but there’s still a ways to go

Moody’s upgrades Boston Scientific, but there’s still a ways to go

March 10, 2009 By MassDevice staff

Out of the frying pan and into … the skillet?

That’s about the size of it for Boston Scientific Corp., which saw its bond rating raised from negative to stable by Moody’s Investors Service. It’s good news, but there’s still a ways to go.

Moody’s upgraded the Natick-based medical device giant’s U.S. public bond rating March 10 from “Ba2” to “Ba1” and its liquidity rating from “SGL-3” to “SGL-2”, while affirming its corporate credit rating at “Ba1.”

While the news take some of the sting out of the downgrade Boston Scientific received from Moody’s back in July 2007, the company’s rating is still a notch below investment grade, relegating it to junk bond status or, in Wall Street parlance, a “fallen angel.”

Ratings below “BB” or investment grade limit companies’ ability to raise capital. For example, under most state laws, it’s illegal for institutions that invest other people’s money to buy into companies that fall below investment grade.

That said, it appears that one of the world’s largest medical device makers is cleaning up its act, at least according to Moody’s. The credit rating agency cited three factors in its decision to upgrade BoSci:

1. Improved covenant cushions provided by recent amendments to the company’s bank facility;
2. Generally steady market share for key drug-eluting stent and cardiac rhythm management products;
3. Ongoing debt repayment and cost-savings initiatives.

While the review was mostly positive, Moody’s said there were still long-term issues clouding the outlook, namely outstanding litigation and Boston Scientific’s highly leveraged debt position, which lingers despite its debt reduction efforts.

CFO Sam Leno said the news validates the company’s moves to strengthen its financial position and drive profitable sales growth, adding that Boston Scientific plans to continue to focus on improving free cash flow, debt repayment and financial discipline.

Filed Under: Business/Financial News, Drug-Eluting Stents

More recent news

  • Medtronic earns CE mark for redo TAVI procedure
  • Natus Neuro launches BrainWatch AI-driven, point-of-care EEG
  • Boston Scientific has positive real-world Acurate Prime TAVI data
  • Johnson & Johnson MedTech launches ultrasound catheter for imaging in cardiac ablation procedures
  • Onward reports more successful BCI implants

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy